Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Leukemia, Mast-Cell × avapritinib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1

Conditions

Recurrence 2 Gastrointestinal Stromal Tumors 2 Systemic Mastocytosis With an Associated Hematologic Neoplasm 1 Neoplasms 1 Mastocytosis, Systemic 1 Leukemia, Mast-Cell 1 Glioblastoma 1

Interventions

ripretinib 1 avapritinib 1 MK 2206 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02561988 2023-03-17

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Blueprint Medicines Corporation

Phase 1 Completed

86 enrolled 1 FDA

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Recurrence, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡